Form 4: Apyx Medical COO Receives Stock Option Grant

Apyx Medical Corporation Chief Operating Officer Shawn David Roman was granted 88,044 stock options on June 11, 2026.

Summary

• Chief Operating Officer Shawn David Roman received a grant of 88,044 stock options.
• The options have an exercise price of $4.65 per share.
• The grant vests ratably over a 36-month period, becoming fully exercisable on June 11, 2029.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not signal a change in company strategy or financial health.

Positives

• Aligns executive compensation with long-term shareholder value through a three-year vesting schedule.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market price volatility may impact the future value of the granted options.

Future Outlook

The options vest ratably over 36 months, indicating a long-term retention incentive for the Chief Operating Officer.

Industry Context

StockSavvy.ai notes that equity-based compensation for C-suite executives is a standard practice in the medical device sector to ensure leadership alignment with corporate performance goals.

Comparison to Industry Standards

• The three-year vesting schedule is consistent with standard corporate governance practices for executive equity grants.

Stakeholder Impact

• Minor potential dilution for shareholders upon the eventual exercise of the options.

Next Steps

• Vesting of options over the next 36 months.

Key Dates

Keywords

Apyx Medical, APYX, Form 4, Insider Trading, Stock Options, Executive Compensation